 The biopharma sector weathered the COVID-19 pandemic fairly well, with the Shares Nasdaq Biotechnology Etf NASDAQ: IBB outperforming the SP 500 Index. This defensive sector also benefited from opportunity in the form of SARS-CoV-2, the virus that causes COVID-19. 